Trials / Recruiting
RecruitingNCT06010342
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Teligene US · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
Detailed description
TL118 is an orally active inhibitor of the tropomyosin receptor kinase (Trk) family consists of TrkA, TrkB, and TrkC. These receptors are encoded by the NTRK1, NTRK2 and NTRK3 genes, and oncogenic fusions of NTRK may cause cancer cells to grow and spread in the body. The purpose of this study is to explore how effective TL118 is for the treatment of patients with solid tumors harboring NTRK gene fusions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TL118 Capsule | Oral administration |
Timeline
- Start date
- 2023-03-16
- Primary completion
- 2026-08-31
- Completion
- 2027-04-30
- First posted
- 2023-08-24
- Last updated
- 2025-07-22
Locations
19 sites across 2 countries: United States, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06010342. Inclusion in this directory is not an endorsement.